Makes generic injectable, inhalation and insulin drugs, including naloxone and Primatene Mist asthma inhaler.
Makes generic injectable, inhalation and insulin drugs, including naloxone and Primatene Mist asthma inhaler.
Builds profit on products with few competitors, making complex injectables and inhalers itself and selling mainly to wholesalers that supply hospitals and pharmacies. Baqsimi, a nasal glucagon for severe low blood sugar acquired from Eli Lilly in 2023, added a branded product to a mostly generic range.
Moat: narrow (scale, regulatory licence, cost advantage). Vertically integrated manufacturing of complex generics/injectables is costly for smaller rivals to replicate.
Headquarters: Rancho Cucamonga, California, US · Founded: 1996 · Employees: 1,976
Size Amphastar Pharmaceuticals (AMPH) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $1.27B, the 2084th largest of 3,085 United States companies the cockpit tracks. Shares closed at $29.71 on 18 Nov 2026.
Performance Over six months the shares gained 64.3%, against -15.6% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 20 in its peer set.
Growth Revenue grew 3.1% over the last twelve months (peer median +7.6%); the operating margin is 18.7% (peer median 0.8%).
Valuation It trades at 9.1× forward earnings against a peer median of 24.0× (cheapest of 11).
Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.4 points above its cost of capital (8.3% WACC).
Credit Amphastar Pharmaceuticals has 1 bond outstanding ($345M).
Short interest Short interest is 10.0% of the free float (30 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $746M | $720M | $732M | $644M | $499M |
| Revenue growth | — | -2% | +14% | +29% | — |
| Gross profit | $334M | $341M | $361M | $344M | $239M |
| EBITDA | $206M | $204M | $263M | $241M | $136M |
| Net income | $99.0M | $98.1M | $160M | $138M | $91.4M |
| Free cash flow | $139M | $121M | $172M | $145M | $64.7M |
| Capital expenditure | $131M | $37.1M | $41.0M | $38.2M | $24.0M |
| Total debt | $692M | $656M | $651M | $624M | $103M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals AMPH | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% |
| Hikma Pharmaceuticals HIK.L | $4.58B | +15% | +2% | 20% | 9.8× | 2.0% |
| Teva Pharmaceutical Industries Limited Sponsored ADR TEVA | $49.3B | +23% | -4% | 19% | 15.0× | 10.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMPH | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.5% | -5.1% | 3rd highest of 20 |
| 6-month return | +64.3% | -15.6% | highest of 20 |
| Distance from 52-week high | -4.2% | -38.9% | highest of 20 |
| Revenue growth (TTM) | +3.1% | +7.6% | 8th lowest of 16 |
| Operating margin | 18.7% | 0.8% | 2nd highest of 16 |
| Forward P/E | 9.1× | 24.0× | cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | 2.5% | 5.2% | 3rd least demanding of 7 |
| Growth delivered (Del g) | +15.5% | +11.0% | 4th highest of 7 |
| Hurdle (Req g minus delivered) | -13.0 pp | -3.4 pp | 3rd least demanding of 7 |
| ROIC minus cost of capital | +0.4 pp | -5.6 pp | 5th highest of 16 |
| EV / EBITDA | 8.4× | 19.0× | 2nd cheapest of 4 |
| Net debt / EBITDA | 2.2× | 4.7× | 3rd least indebted of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| GH Research GHRS | United States | $1.25B | -19% | n/a | n/a | n/a | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.25B | -16% | +14% | 19% | 11.9× | 3.4% | +27.9% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.24B | -27% | -3% | 1% | 18.6× | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 60.7× | n/a | n/a |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.24B | -53% | n/a | n/a | n/a | n/a | n/a |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.23B | -1% | n/a | n/a | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | n/a | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% | +3.9% |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.23B | -10% | -29% | 3% | 21.3× | 7.0% | -5.3% |
| Idorsia IDIA.SW | Switzerland | $1.22B | -9% | -5% | -70% | n/a | n/a | n/a |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |
| D&D Pharmatech 347850.KS | South Korea | $1.22B | -49% | -77% | -2,324% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Harrow HROW | United States | $1.21B | +4% | +21% | 1% | 26.8× | n/a | n/a |
Amphastar Pharmaceuticals has 1 bond outstanding with $345M face value.